Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06865339 · ClinicalTrials.gov registry record · Phase 2
Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer
A Phase 2 study of NSCLC and Locally Advanced, sponsored by Nitin Ohri.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
- 1
- Study location
NCT06865339: Recruiting Phase 2 study of NSCLC and Locally Advanced, sponsored by Nitin Ohri.
NCT06865339 is a Phase 2 study of NSCLC and Locally Advanced that is actively recruiting participants, run by Nitin Ohri. The registered enrollment target is 76 participants, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (66% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06865339, a Phase 2 study of NSCLC and Locally Advanced, is actively recruiting participants, sponsored by Nitin Ohri.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
- 1
- Study location
Study Summary
Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).
Primary Outcome
ORR to induction therapy will be evaluated by fluorodeoxyglucose (FDG) FDG-PET scan using Positron Emission Tomography Response Criteria in Solid Tumors (PERCIST) criteria. Pre-and post-treatment maximum standardized uptake value (SUV) levels following PERCIST criteria will be assessed. Specifically, the percentage of patients who experience either a complete metabolic response (CMR) or partial metabolic response (PMR) based on changes in FDG uptake will be determined and quantified using the fo
Conditions Studied
Interventions
- DRUG Cemiplimab
- RADIATION Radiotherapy
- DRUG Fianlimab
- DRUG Platinum Doublet Chemotherapy (PDC)
Study Locations (1)
New York
- Montefiore Einstein Comprehensive Cancer Center (MECCC) - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2027-08 |
| Phase | Phase 2 |
What NCT06865339 shows while recruiting
NCT06865339 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 76 participants, a relatively small participant target, below the 223-participant average among 71 other NSCLC trials with a reported enrollment target (66% lower).
The record links to 2 conditions, with NSCLC appearing as the primary indexed condition, and to 4 interventions - of which Cemiplimab is the first listed.
NCT06865339 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06865339 about?
NCT06865339 is a clinical study titled "Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer". Determine anti-tumor efficacy by characterizing response rates on positron emission tomography (PET) following three cycles of induction immunotherapy with cemiplimab and fianlimab without chemotherapy for locally advanced non-small cell lung cancer (LA-NSCLC).
What is the current status of trial NCT06865339?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2025-08-07. Estimated completion is 2027-08.
What conditions does trial NCT06865339 study?
This clinical trial studies the following conditions: NSCLC, Locally Advanced.
What interventions are being tested in trial NCT06865339?
The interventions under investigation include: Cemiplimab (DRUG), Radiotherapy (RADIATION), Fianlimab (DRUG), Platinum Doublet Chemotherapy (PDC) (DRUG).
Who is sponsoring clinical trial NCT06865339?
This trial is sponsored by Nitin Ohri, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06865339 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NSCLC
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06865339's enrollment target sits among peer trials
76 44th of 71 higher than 26 of 71 other NSCLC trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NSCLC trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Disease
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
RECRUITING · Phase 2
-
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02615184 · 76 participants · Phase 2
A Study to Check the Safety of Dexlansoprazole and Learn If it Can Heal Erosive Esophagitis (EE) and Keep it Healed in Children 2 to 11 Years Old
- NCT02821741 · 76 participants · NA
Effects of External Ear Stimulation on Pain Perception and Mood
- NCT03019757 · 76 participants
Distinguishing Between Alzheimer's Disease, Lewy Body Dementia, and Parkinson's Disease
- NCT03353584 · 76 participants · NA
Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI